Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | INPP5D | Q92835 | 2/20 | 0.98 |
| ▸ | CDC25A | P30304 | 4/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | POLA1 | P09884 | 1/20 | 0.64 |
| ▸ | OSBP | P22059 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.57 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817635 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL1881196 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL21946613 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL23016826 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL12279525 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL23645781 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL22712829 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL24104271 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL21589991 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE | |
| SCHEMBL1163654 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP2C19INPP5DCDC25ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478643-B2 | Compositions and methods for the prevention or treatment of rheumatoid arthritis | RHODE ISLAND HOSPITAL (US) | 2025-11-25 | — | — | US | claimed |
| US-20240197775-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS | RHODE ISLAND HOSPITAL | 2024-06-20 | — | — | US | claimed |
| WO-2022216615-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS | RHODE ISLAND HOSPITAL (US) | 2022-10-13 | — | — | WO | claimed |
| US-12478643-B2 | Compositions and methods for the prevention or treatment of rheumatoid arthritis | RHODE ISLAND HOSPITAL (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240197775-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS | RHODE ISLAND HOSPITAL | 2024-06-20 | — | — | US | disclosed |
| US-11952328-B2 | Selective ship inhibitors for treating disease | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4169902-A1 | SPERMINE DERIVATIVES AS HEPARIN ANTIDOTES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022216615-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS | RHODE ISLAND HOSPITAL (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20210186989-A1 | ENHANCED TRAINED IMMUNITY IN MYELOID CELLS BY SHIP-1 INHIBITION | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (ES) | 2021-06-24 | — | — | US | disclosed |
| US-10988533-B2 | Anti-pre-BCR antagonists and methods | UNM RAINFOREST INNOVATIONS (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3801555-A1 | ENHANCED TRAINED IMMUNITY IN MYELOID CELLS BY SHIP-1 INHIBITION | Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) (ES) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020081852-A1 | SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019234189-A1 | ENHANCED TRAINED IMMUNITY IN MYELOID CELLS BY SHIP-1 INHIBITION | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2019-12-12 | — | — | WO | disclosed |
| US-20180022805-A1 | ANTI-PRE-BCR ANTAGONISTS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20170151262-A1 | SHIP INHIBITION TO INDUCE ACTIVATION OF NATURAL KILLER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| EP-3157529-A1 | SHIP INHIBITION TO INDUCE ACTIVATION OF NATURAL KILLER CELLS | The Research Foundation for The State University of New York (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016127043-A1 | ANTI-PRE-BCR ANTAGONISTS AND METHODS | STC.UNM (US) | 2016-08-11 | — | — | WO | disclosed |
| EP-3016660-A1 | SHIP INHIBITION TO COMBAT OBESITY | The Research Foundation for the State University of New York (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015195812-A1 | SHIP INHIBITION TO INDUCE ACTIVATION OF NATURAL KILLER CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015003003-A1 | SHIP INHIBITION TO COMBAT OBESITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478643-B2 | Compositions and methods for the prevention or treatment of rheumatoid arthritis | CD47, PRMT1, ARG1 | CYP2D6 4818/4885CYP2C19 4831/4885INPP5D 1373/4885 |
| US-20170151262-A1 | SHIP INHIBITION TO INDUCE ACTIVATION OF NATURAL KILLER CELLS | CD58, CD47, MCL1 | CYP2D6 4817/4885CYP2C19 4815/4885INPP5D 238/4885 |
| US-20240197775-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS | CD47, PRMT1, ARG1 | CYP2D6 4818/4885CYP2C19 4831/4885INPP5D 1373/4885 |
| US-20210186989-A1 | ENHANCED TRAINED IMMUNITY IN MYELOID CELLS BY SHIP-1 INHIBITION | CD47, MYD88, IRAK1 | CYP2D6 4805/4885CYP2C19 4861/4885INPP5D 261/4885 |
| US-11952328-B2 | Selective ship inhibitors for treating disease | PPM1A, MTMR1, PPM1B | CYP2D6 4746/4885CYP2C19 4796/4885INPP5D 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.